Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cis-platinum vestibular toxicity

S D Schaefer, C G Wright, J D Post

    Cancer
    |March 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Cisplatin chemotherapy can cause hearing loss. This study reports the first case of cisplatin-induced vestibular toxicity and introduces a new testing program for platinum-based drug side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A sampling method to determine insecticide residues on surfaces and its application to food-handling establishments.

    Environmental monitoring and assessment·2013
    Same author

    DDVP residues in air following application to a tobacco-storage warehouse.

    Environmental monitoring and assessment·2013
    Same author

    Distribution of chlorpyrifos in air and on surfaces following crack and crevice application to rooms.

    Environmental monitoring and assessment·2013
    Same author

    A new spontaneous mutation in the mouse protocadherin 15 gene.

    Hearing research·2006
    Same author

    Pilot study using SELDI-TOF-MS based proteomic profile for the identification of diagnostic biomarkers of thyroid proliferative diseases.

    Journal of proteome research·2006
    Same author

    DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.

    British journal of cancer·2005
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Ototoxicology
    • Neuroscience

    Background:

    • Cis-diamminedichloroplatinum (cisplatin) is a widely used chemotherapeutic agent.
    • Nephrotoxicity and ototoxicity are known adverse effects of cisplatin therapy.
    • Previous research on cisplatin's ototoxicity has primarily focused on auditory function.

    Observation:

    • This report documents the first known instance of vestibular toxicity in a patient undergoing platinum-based therapy.
    • The patient experienced symptoms indicative of vestibular dysfunction following cisplatin treatment.

    Findings:

    • The study confirms vestibular toxicity as a potential side effect of cisplatin.
    • A prospective vestibular testing program was implemented to systematically evaluate this toxicity.

    Related Experiment Videos

    Implications:

    • This research highlights the need to consider vestibular function when monitoring patients on cisplatin.
    • The developed testing program may aid in early detection and management of platinum-induced vestibular damage.
    • Further investigation is warranted to understand the mechanisms and prevalence of cisplatin-induced vestibular toxicity.